Dr Ajit Kumar, Dr Aradhna Tripathi


Introduction- The present study was conducted to assess the efficacy and toxicity profile of concurrent weekly cisplatin dosing as compared to 3 weekly cisplatin  with radiotherapy in patients of cervical cancer and also to evaluate the compliance among them.

Methodology- This was prospective randomized comparative study at tertiary centreon patients of locally advanced cervical cancer. Patients were randomly divided into 2 groups and patients of group 1 received EBRT with weekly cisplatin whereas patients of group 2 received EBRT with 3 weekly cisplatin. All the patients were followed up for assessment of compliance, acute toxicities and treatment response.

Results- The study included 80 patients which were randomized into 2 groups. The population in two groups was comparable in baseline characteristics. No statistically significant difference in occurrence of acute toxicities between the participants of two groups was observed (p>0.05). Clinically, complete response was noted in 82.5% and 90% patients in group 1 and group 2 respectively. However the observed difference in response was not statistically significant (p>0.05).

Conclusion-The present study documented similar response and toxicity profile of both the regimens and thus concurrent weekly or 3 weekly cisplatin along with radiotherapy can be used with equal effectiveness in the treatment of cervical cancer.


Concurrent cisplatin, weekly, triweekly, central India, Cervical cancer

Full Text:



WHO. Cancer Cervix 2018 [Available from: diagnosis-screening/cervical-cancer/en/. Accessed on 10 February 2020.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020 Feb 1;8(2):e191-203.

Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer Accessed on 10 February 2020.

Whitney, C.W., Sause, W., Bundy, B.N., Malfetano, J.H., Hannigan, E.V., Fowler, Jr, W.C., Clarke-Pearson, D.L. and Liao, S.Y., 1999. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology, 17(5), pp.1339-1339.

Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.

Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-43.

Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-61.

Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.

NCI Clinical Announcement. Concurrent Chemoradiation for Cervical Cancer (Report). U.S. Department of public health; 1999.

Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (TACO) accessed on 10 Feb 2020.

Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, et al. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2011;81:e577-81.

Lee HN, Lee KH, Lee DW, Lee YS, Park EK, Park JS, et al. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer. Int J Gynecol Cancer 2011;21:128-36.

Chumworathayi B, Suprasert P, Charoenkwan K, Srisomboon J, Phongnarisorn C, Siriaree S, et al. Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: A randomized comparison of treatment compliance. J Med Assoc Thai 2005;88:1483-92.

Akhila Vishwanathan C.Halperin DEW et al P and, By BP and practice of radiation oncology. Perez and Brady’s Principles and practice of radiation oncology 6th edition by Edward Chapter 69 uterine cervix May 06, 2013.

Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002;38:223-30

Anusha Konakalla V L, Das P, Swapna J, Jena A, Radhika K, Rao B S, Kuna J, Jagannathrao Naidu K V, Subramanian B V. A prospective randomised study on comparison of weekly versus 3 weekly cisplatin chemotherapy as an adjunct to radiotherapy in treatment of carcinoma of the uterine cervix. J Clin Sci Res 2018;7:12-8


  • There are currently no refbacks.